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Common marmosets (Callithrix jacchus) have recently gained popularity in biomedical
research as models of aging research. Basically, they confer advantages from other
non-human primates due to their shorter lifespan with onset of appearance of aging at
8 years. Old marmosets present some markers linked to neurodegeneration in the brain
such as amyloid beta (Aβ)1−42 and Aβ1−40. However, there are no studies exploring
other cellular markers associated with neurodegenerative diseases in this non-human
primate. Using immunohistochemistry, we analyzed brains of male adolescent, adult,
old, and aged marmosets. We observed accumulation of Aβ1 and A in the−40 β1−42
cortex of aged subjects. Tau hyperphosphorylation was already detected in the brain of
adolescent animals and increased with aging in a more fibrillary form. Microglia activation
was also observed in the aging process, while a dystrophic phenotype accumulates
in aged subjects. Interestingly, dystrophic microglia contained hyperphosphorylated
tau, but active microglia did not. These results support previous findings regarding
microglia dysfunctionality in aging and neurodegenerative diseases as Alzheimer’s
disease. Further studies should explore the functional consequences of these findings
to position this non-human primate as animal model of aging and neurodegeneration.
Keywords: aging, neurodegeneration, animal models, non-human primate
INTRODUCTION
Our world population is constantly increasing, and life expectancy in developing countries does
as well (World Health Organization, 2015). Aging is characterized by an increasing morbidity
and functional decline that eventually results in the death of an organism. Aging is the largest
risk factor for several human diseases (López-Otín et al., 2013), and nowadays, cognitive decline
has been observed to prevail in aged subjects (Hedden and Gabrieli, 2004). Currently, there are
no treatments to cure or prevent cognitive decline due to aging or neurodegenerative diseases as
Alzheimer’s disease (AD). Diverse animal models of aging have been developed to gain a better
understanding of the biological causes of senescence, longevity, or disease (Woodruff-Pak, 2008;
Yeoman et al., 2012). Animals have been mechanically drug-induced or genetically manipulated to
model the aging process (Woodruff-Pak, 2008; Tomobe and Nomura, 2009; Bilkei-Gorzo, 2014;
Mitchell et al., 2015). Likewise, invertebrates are also employed (Yeoman and Faragher, 2001;
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Woodruff-Pak, 2008; Chiu et al., 2011). These models have
proven to be useful in the study of physiological processes related
to aging and neurodegeneration. Nevertheless, non-human
primates have gained popularity in aging research due to their
ability to provide a better anatomical and pathophysiological
representation of the human central nervous system (CNS;
Scientific Committee on Health and Environmental Risks, 2009;
Teo et al., 2012). Cognitive capabilities and memory task related
to human conditions are more closely assessed in non-human
primates than in other mammals (Huang et al., 2016). Moreover,
the progression of human diseases is better reflected in non-
human primates (Teo et al., 2012). Considerable research has
focused on the Old World monkeys (Carlsson et al., 2004; Huang
et al., 2016). However, for aging studies, smaller New World
species, like the marmoset, are attractive candidates due to their
shorter life span with onset of appearance of aging at 8 years
(Abbott and Barnett, 2003) while a significant reduction in early
adult mortality is seen in captivity where marmosets can live up to
16–18 years (Tardif et al., 2011). Common marmosets originated
from the Amazon, and are characterized by a small body size
(20–30 cm and 250–600 g), an accelerated life history (sexually
mature at 1.5 years), and a capacity to produce high numbers of
offspring (∼12 over 3 years from one female; Okano et al., 2012).
In addition, there is a high genetic homology to humans (Ross
et al., 2012). Therefore, marmosets are nowadays widely used for
biomedical research (for review see t’Hart et al., 2012).
Aging in marmosets causes diverse alterations in the CNS
(Tardif et al., 2011), such as decrease neurogenesis in the dentate
gyrus of the hippocampal formation (Leuner et al., 2007), loss of
calbindin positive cells in the basal forebrain (Wu et al., 2003),
and cortical amyloid plaques (Geula et al., 2002). However, there
is a lack of studies regarding the presence of neurodegenerative
markers in this non-human primate.
In this study, we aimed to assess the presence of human
neurodegenerative markers such as hyperphosphorylation of
tau protein and activation of microglia cells. We have
detected amyloid plaques in the cortex of aged subjects. An
abnormally hyperphosphorylated tau protein was present already
in adolescent marmosets, whereas those alterations were more
pronounced with aging. Microglia phenotype differs across ages,
as adult and old groups had abundant active microglia cells, while
dystrophic cells increased significantly in aged animals compared
to younger subjects. Importantly, tau hyperphosphorylation and
aggregation were present only in dystrophic microglia cells.
Thus, the presence of these neurodegenerative markers position
marmosets as a potential model of neurodegeneration related to
aging.
MATERIALS AND METHODS
Subjects
Laboratory-bred common marmoset monkeys (Callithrix
jacchus) were housed at the German Primate Center, Göttingen,
Germany, under standard conditions complying with the
European Union guidelines for the accommodation and care
of animals used for experimental and other scientific purposes
(2007/526/EC). All animal experiments were performed in
accordance with the German Animal Welfare Act, which
strictly adheres to the European Union guidelines (EU directive
2010/63/EU) on the use of non-human primates for biomedical
research. Experienced veterinarians and caretakers constantly
monitored the animals. The experiments were ethically approved
by the Lower Saxony State Office for Consumer Protection and
Food Safety (LAVES, Oldenburg, Germany). Animals did not
present neurological disorders or other injuries that can cause
trauma to the CNS.
Tissue Preparation
Brains of male marmosets of different ages were used in the
current study: two adolescent (A: mean age 1.6 years), two adults
(Ad: mean age 5.5 years), five old (O: mean age 11 years), and
two aged (Ag: mean age 18 years; based on age classification by
Abbott and Barnett, 2003). All animals were anesthetized with
GM II and received, after loss of consciousness, an intraperitoneal
injection of ketamine (400 mg/kg body weight). Bodies were
transcardially perfused with cold (4◦C) saline (0.9% NaCl) for
5 min. Subsequently, for fixation of the brains, cold (4◦C) 4%
paraformaldehyde (PFA) in 0.1 M phosphate buffer, pH 7.2, was
infused for 15 min. The brains were removed and postfixed in
fresh 4% PFA at 4◦C. All brains had been stored in 4% PFA for
variable lengths of time. Upon receipt in the laboratory, tissue was
washed with 0.1 M phosphate buffered saline (PBS: 0.14 M NaCl,
2.95 mM KCl, 8.09 mM Na2HPO4, 1.47 mM KH2PO4; pH 7.4)
thoroughly. Four days before sectioning, tissue was immersed in
30% sucrose in PBS and kept at 4◦C.
Coronal sections (40 µm) were obtained from the medial
temporal area – temporal, parietal and entorhinal cortex, and
hippocampal formation (Bregma 8.00–0.80 mm according to
Paxinos et al. (2012) by use of sliding microtome (Leica RM2235).
All sections were immediately immersed in cryoprotectant
solutions, one for light microscopy [300 g sucrose (J.T. Baker);
400 mL of 0.1M PB and 300 mL ethylene glycol (Sigma), for 1 L]
and other for immunofluorescence [300 g sucrose; 10 g polyvinyl-
pyrrolidone (PVP-40, Sigma); 500 mL of 0.1M PB and 300 mL
ethylene glycol, for 1 L] and stored at−20◦C until use.
Immunohistochemistry
All sections were pretreated with formic acid (J.T. Baker)
during 15 min and with citrate buffer 20X (Sigma) at 94◦C for
10 min, except for sections incubated with anti Iba-1and AT-100.
Thereafter, slides were permeabilized with 0.2% Triton X100 in
PBS (0.2% PBS-triton) during 20 min. Sections were washed in
PBS and incubated in 0.3% H2O2 (in PBS) for 10 min to inactivate
endogenous peroxidase activity. The following washing steps
were performed three times, 10 min each, in 0.2% PBS-triton.
To block potential non-specific antibody binding, all sections
were incubated in 5% BSA (bovine serum albumin; Sigma) in
PBS for 5 min. Subsequently, sections were incubated with the
following antibodies: pTau (Thr231; IgG, BioScience, Cat. No.
MBS857154, 1:500), AT-100 (IgG, Jackson Immuno Research,
Cat. No. 111-175-166), Aβ1−40 (IgG, Invitrogen, Cat. No. 44136,
1:200), Aβ1−42 (IgG, Invitrogen, Cat. No. 44344, 1:200), Iba-1
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(IgG, Wako Chemicals, Cat. No. 019-19741, 1:300), and Alz-
50 (IgM, kindly donated by Dr. Francisco García-Sierra, 1:5000)
diluted in 0.2% PBS-triton.
For immunohistochemistry against tau (Phospho Thr231),
Aβ1−40 and Aβ1−42, after washing, sections were incubated with
biotinylated secondary antibody (IgG, Vector Laboratories, Cat.
No. BA-1100, 1:500) diluted in 0.2% PBS-triton during 2 h
at room temperature. Subsequently, the sections were washed
and incubated with the avidin-biotin complex (ABC Kit; Vector
Laboratories) in 0.2% PBS-triton for 2 h, according to the
producer’s instructions. Finally, antibody binding was visualized
with the chromogen 3,3′-diaminobenzidine (DAB Peroxidase
Substrate Kit; Vector Laboratories) 0.025%, with 0.01% H2O2 as
a catalytic agent. Control sections were processed without the
primary antibody. The sections were then washed, mounted on
glass slides and left to dry overnight. Dry sections were cover
slipped with mounting medium Entellan (Merck).
For Alz-50 and anti-Iba-1 antibodies, sections were incubated
with secondary horseradish peroxidase-conjugated antibodies
(for Alz-50, anti-mouse IgM, 1:500, kindly donated by Dr.
Francisco García Sierra); for anti-Iba-1 (anti-rabbit IgG, Thermo
Scientific, Cat. No. 65-6120, 1:500) in 0.2% PBS-triton. Hydrogen
peroxide (0.01%) and DAB (0.06%) in 0.2% PBS-triton was used
to develop the horseradish peroxidase enzymatic reaction. The
enzymatic reaction was stopped with 0.2% PBS-triton and then
sections were mounted with Entellan (Merck) as described above.
Immunofluorescence
Sections were pretreated with formic acid for 15 min, followed by
incubation in citrate buffer 20X at 94◦C for 10 min. Sections were
permeabilized with 0.2% PBS-triton during 20 min. Thereafter,
sections were treated with 5% BSA for 5 min, and incubated
with the primary antibodies: AT-100 (IgG, Jackson Immuno
Research, Cat. No. 111-175-166, 1:500), anti-Iba-1 (IgG, Wako
Chemicals, Cat. No. 019-19741, 1:300), and Alz-50 (IgM, kindly
donated by Dr. Francisco García-Sierra, 1:5000) in the presence
of 5% horse serum (Vector Laboratories, S-2000) during 48 h
(4◦C). One IgG and one IgM primary antibody was used for
double labeling. The sections were then washed with 0.2% PBS-
triton, and incubated with secondary antibodies: FITC (anti-
mouse IgM, kindly donated by Dr. Francisco García Sierra);
Cy5 (anti-rabbit IgG, Jackson Immuno Research, Cat. No. 111-
175-144); Cy5 (anti-mouse IgG, Jackson Immuno Research, Cat.
No. 111-175-166); Alexa488 (anti-mouse IgG, Jackson Immuno
Research, Cat. No. 115-545-166), with working dilution 1:500
in all cases, diluted in 0.2% PBS-triton. Control sections were
processed without the primary antibody. All sections were co-
incubated with DAPI (Invitrogen, 1:1000) in 0.2% PBS-triton
during 30 min. The sections were then washed, mounted on glass
slides. Dry sections were cover slipped with mounting medium
VectaShield (Vector Laboratories).
Image Acquisition
Nikon Eclipse 80i light microscope equipped with a Nikon DS-
Ri1 camera was used to acquire bright-field images under 20×
and 40× objectives, whereas for fluorescent labeling a laser
scanning microscopy (Leica TCS-SP8) with argon (488 nm), and
helium/neon (543 nm) lasers was used. Both lasers were always
used with optimized pinhole diameter. Confocal images were
obtained as z-stacks of single optical sections. Stacks of optical
sections were superimposed as a single image by using the Leica
LAS AF 2.6.0 build 7268 software.
Morphometry
The immunoreactivity of phospho Thr231 (pTau231), AT-100
and Alz-50 was quantified as follows: For each subject, two brain
slices (at least 800 µm apart) were imaged. Thereafter, from each
slice we obtained the following images: 14 images from dorsal
hippocampus (four from each CA1, CA2, and CA3, and four
from dentate gyrus), eight images from entorhinal cortex (layers
VI-III), 14 images from parietal (layers VI-III), and 14 images
from temporal cortex (layers VI-III). The total area covered
from each region was calculated as the total number of images
multiplied by 276360 µm2 (area of a single image). We used
ImageJ software (NIH, Bethesda, MD, USA) to determine the
area occupied by tau aggregates. To determine the percentage of
area in a determined region, the sum of the areas covered by tau
aggregates was divided by the total area, and then, multiplied by
100.
For microglia quantification, iba-1 positive cells located in
the dentate gyrus were analyzed. At least three slides from
each age group (800 µm apart from each other) were imaged.
The number of cells with different morphological state per
unit area (number of cells/number of images × single image
area 0.069 mm2) was scored in 100 ± 10 images. Based
on their morphological characteristics they were classified as:
resting (displaying a slight ramified morphology and small
rounded soma), active (hypertrophic soma and ramified cells
with extensively thick and branched processes), and dystrophic
(loss of fine branches, presence of shortened tortuous processes
and/or cytoplasmic fragmentation; Streit et al., 2004, 2009). The
presence of cytoplasmic spheroids alone was not considered a
criterion sufficient for scoring as dystrophic cells.
Statistical Analysis
For analysis of single immunohistological markers we used one-
way ANOVA, followed by a Tukey’s post hoc test. For microglia
phenotype across ages, we used a two-way ANOVA followed
by a Bonferroni’s post hoc test. Pearson’s correlation coefficient
and probability p-value, which describe the significance of
the correlation, were used to assess the relationships between
tau hyperphosphorylation (pTau231 and AT100) and tau
conformational changes (Alz50). Differences were considered
statistically significant when p ≤ 0.05. Data are presented as
means± SEM.
RESULTS
Amyloid Diffuse Plaques Were Present in
Cortex of Aged Marmosets
Diffuse plaques (without visible fibrillar Aβ or dystrophic
neurites) and compact plaques (mature plaques intensely labeled
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FIGURE 1 | Compact and diffuse Aβ plaques in the cortex of aged marmoset. Aβ1−42 plaques in entorhinal cortex (A,D), retroinsular area (B,E), and parietal
cortex (C,F): compact (arrow in D,F) and diffuse plaques (arrowhead in D,E) are observed in cortex. Aβ1−40 diffuse plaques in the entorhinal (G) and temporal cortex
(H): notice the presence of Aβ1−40 aggregates surrounding vascular vessels (asterisk). (A–C) captured at 20X and (D–F) captured at 40X.
with Aβ) were identified in marmoset brains, according to
Dickson and Vickers (2001). We observed accumulation of
Aβ1−40 and Aβ1−42 in the cortex of aged animals (entorhinal,
retroinsular, and parietal cortices). A large accumulation of
Aβ1−42 in the form of diffuse and compact plaques was found
in parenchyma. No Aβ1−42 positive staining was observed in the
hippocampal formation. Aβ1−40 was present only in the cortex,
mainly around blood vessels as diffuse aggregates; however, it
was less abundant than Aβ1−42 (Figure 1). We did not detect
Aβ1−40/1−42 positive staining in other ages (i.e., adolescent, adult,
old).
Presence of Abnormal
Hyperphosphorylation of Tau across
Ontogeny of Marmoset
Using antibodies to detect phosphorylation in relevant residues
of the tau aggregation process (PhosphoTau-Thr231 and
AT100; Jicha et al., 1997b; Zheng-Fischhöfer et al., 1998) and
conformational changes in the protein (Alz50), we detected
abnormally hyperphosphorylated tau in the medial temporal area
and parietal cortex of the marmosets.
Presence of pTau231 Hyperphosphorylated Site
(Thr231)
First, we aimed to determine whether marmosets present
hyperphosphorylated tau protein immunoreactive (ir) labeling
in the brain (Jicha et al., 1997b). Adolescent subjects showed a
light and spread pTau231-ir distribution in several regions of the
medial temporal area (hippocampus, entorhinal, and temporal
cortex), while adults and old individuals had a more abundant
and intense labeling. In the aged subjects, pTau231-ir was heavily
present in all the regions analyzed (hippocampus, entorhinal,
temporal and parietal cortices; Figure 2). Quantification of
pTau231-ir in these areas showed significant differences between
old and aged subjects versus adult and adolescent groups
(Figure 3).
AT100 Was Lightly Present in Adolescent and Adult
Individuals, but It Increases with Aging
AT100 labels a phosphorylation site at residues Thr212 and
Ser214 (Zheng-Fischhöfer et al., 1998). In the brain of marmosets,
AT100-ir was detected as aggregates in the cytoplasm in all
regions at all ages. In contrast, larger AT100-ir inclusions
were observed in old and aged marmosets (Figure 4). Further
quantification analysis indicated a significant increase of AT100-
ir in old and aged animals, versus those adolescent and adult
(Figure 5).
Conformational Changes of Tau Protein Were
Detected in All Subjects but Increase with Aging
Alz50 binds to two discontinuous sequences of tau, one
consisting of residues 5–15 at N-terminus and another in
the residues 312–322 of the third microtubule-binding repeat
domain (Carmel et al., 1996; Jicha et al., 1997a). Alz50-ir depends
on the self-folding of N-terminus onto the third microtubule-
binding repeat domain, thus allowing the recognition of early
aggregation of tau protein (Weaver et al., 2000).
Our results show Alz50-ir in adolescent and adult subjects as a
faint staining mainly in cytoplasmic compartments (Figures 6A–
H). In old subjects, a stronger Alz50-ir was located in cytoplasm
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FIGURE 2 | Immunohistochemistry for pTau231 in different brain regions of the marmoset. Adolescent subjects (A–D) present few pTau231 aggregates in
CA3 region of the hippocampus (A), but there was a lack of staining in the rest of the brain areas analyzed. In adult individuals (E–H) a similar labeling was observed,
where few pTau231 aggregates were present in entorhinal cortex (G). The old group (I–L) presented abundant pTau231 aggregates in all regions analyzed, and
labeling was stronger in the cytoplasmic area. In aged animals (M–P), pTau231 accumulates in larger and more abundant aggregates in soma and dendrites of
neurons in all brain areas analyzed. Inclusions are indicated by arrows. Scale bar 50 µm.
FIGURE 3 | Percentage of area occupied by pTau231-ir in
hippocampus and cortices (entorhinal, temporal, and parietal) of
marmoset at different ages (A, adolescents; Ad, adults; O, old; and Ag,
aged). One-way ANOVA followed by Tukey post hoc test. (∗p < 0.05;
∗∗p < 0.01; ∗∗∗p < 0.001).
mainly in a fibrillary form. Moreover, Alz50-ir was present
in neurons with a principal cell-like-morphology, but also
in structures that resemble glial cells (Figures 6I–L). Aged
individuals had stronger Alz50-ir with cytoplasmic fibrillary
inclusions and labeling of dendrites of principal neurons, and
a dense Alz50-ir in glia like-cells (Figures 6M–P). Statistical
analysis showed a significant increase of Alz50-ir in aged
animals compared to younger ones (300% increase compared to
old, and over 800% increase compared to adolescent subjects;
Figure 7).
Correlation of Tau Hyperphosphorylation versus
Conformational Change in Marmoset Brain
In order to determine the strength of the association of markers
of hyperphosphorylation with those related to conformational
changes of tau protein, Pearson correlation was used. In all
regions analyzed, there was a positive correlation between
pTau231/AT100 with Alz-50-ir: pTau231-ir was significantly
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FIGURE 4 | Immunohistochemistry for AT-100 in different brain regions of marmoset. Adolescent animals (A–D) presented a light phosphorylation of tau
residues Thr212 and Ser214 in all regions analyzed. Adult subjects (E–H) showed same pattern of immunoreactivity. Old individuals (I–L) had a stronger labeling as
AT100-ir appears in cytoplasm, but also as inclusions in the nucleus of the cells. In the aged individuals (M–P) AT100-ir increased in all brain regions of the brain
analyzed (cytoplasmic and nuclear inclusions). Inclusions indicated by arrows. Scale bar 50 µm.
FIGURE 5 | Percentage of area occupied by AT100-ir in hippocampus
and cortex (entorhinal, temporal, and parietal) of marmoset at
different ages (A: adolescents, Ad: adults, O: old and Ag: aged). One
way ANOVA, post hoc analysis Tukey. (∗p < 0.05; ∗∗p < 0.01; ∗∗∗p < 0.001).
correlated to Alz50-ir in entorhinal (r = 0.807, p < 0.01)
and parietal (r = 0.931, p < 0.001) cortices whereas AT100-
ir and Alz50-ir were significantly correlated in hippocampus
(r = 0.702, p < 0.05) and temporal cortex (r = 0.688,
p < 0.05). The slope of the linear regression was in all cases
higher for pTau231-ir than for AT100 (Figure 8). Moreover,
when tau markers where plotted against age, a similar pattern
was observed. PTau231 presented the highest correlation in
entorhinal (r = 0.934, p > 0.0001) and parietal (r = 0.936,
p > 0.0001) cortices compared to AT100-ir and Alz50-
ir. However, in hippocampus and temporal cortex, although
pTau231-ir was higher than AT100-ir, correlation analysis
indicated a stronger association of AT100-ir (r = 0.834, p > 0.01
and r = 0.873, p > 0.001, respectively) with age (Supplementary
Figure S1).
Morphological Alterations of Microglia
Cells in Marmosets
Changes in Microglia Phenotype with Aging
It has been described that microglia are subject to different
morphological alterations related to their active state during
aging and neurodegeneration (von Eitzen et al., 1998; Streit
et al., 2004, 2009; Simmons et al., 2007; Xue and Streit, 2011).
Microglial activation can lead to uncontrolled or prolonged
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FIGURE 6 | Immunohistochemistry for Alz50 in different brain regions of marmoset. Adolescent subjects (A–D) present a faint Alz50 positive labeling. In
adults (E–H) a similar pattern was observed, however, with stronger immunoreactivity. Old subjects (I–L) presented an intense and abundant Alz50-ir in neurons
(arrow) and glia cells (arrowhead). In aged subjects (M–P), Alz50-ir was strongly present in all brain regions, where also dendrites were dense labeled. Fibrillary
inclusions are observed in neurons (arrow) and glia cells (arrowhead). Fibrillary inclusions are observed in principal like-cells (∗). Scale bar 50 µm.
FIGURE 7 | Percentage of immunoreactivity for Alz50 in hippocampus
and cortex (entorhinal, temporal, and parietal) of marmoset at
different ages (A: adolescents, Ad: adults, O: old, and Ag: aged). One
way ANOVA, post hoc analysis Tukey. (∗p < 0.05; ∗∗p < 0.01).
neuroinflammation, a potentially harmful event that can result
in cellular damage. Prolonged microglia activation also leads
to the loss of function and a dystrophic phenotype (Streit
et al., 2004). We focuses our study on the classification
microglia as resting, active, or dystrophic state, based on
previous studies (Streit et al., 2004, 2009). The visualization
of microglia with anti-iba1 clearly shows these cells under
resting state (characterized by round soma and long extended
processes), active (characterized by hypertrophy of the soma
and processes), and dystrophic state (characterized by abnormal
cytoplasm, fragmented and helicoidally process; Figure 9).
We then sought to determine the microglia’s phenotype in
the dorsal hippocampal region of adolescent, adult, old, and
aged individuals. The total number of microglia was similar
among all ages (range: 101–156 cells; Figure 10). However,
the morphological classification indicates an age-dependent
phenotype. Resting microglia was the most prominent phenotype
across ages, being higher in adolescent animals compared to
old and aged subjects (Figure 10). Active microglia presented a
more homogeneous presence in all ages, but it was significantly
decreased in the aged subjects compared to adolescent, adult,
and old animals (Figure 10). Dystrophic microglia revealed the
lowest frequency across the ontogeny; however, it was higher
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FIGURE 8 | Correlation analysis of phosphorylated tau markers versus Alz-50-ir in the hippocampal area and entorhinal, temporal, and parietal
cortices. Pearson correlation (r) was used for statistical analysis; p indicates significant differences.
in the aged animals compared to adolescent and adult animals
(Figure 10).
Dystrophic Microglia Presented
Hyperphosphorylation and Conformational Changes
in Tau
As we detected the presence abnormal tau hyperphosphorylation
in structures that resembled glia cells (Figures 4 and 6), we aimed
to segregate the presence of Alz50-ir and AT100-ir regarding
the microglia’s phenotype. We focused on the dentate gyrus as
this area presented a large amount of dystrophic microglia. In
the aged animals, AT100 was present in every dystrophic cell
as dense inclusions, but active microglia did not show AT100-
ir (Figure 11). In addition, Alz50-ir was highly present in
dystrophic microglia, while active microglia did not present any
labeling (Figure 11).
As we observed few dystrophic microglia cells in adolescent
and adult marmosets (Figure 10), we sought to determine
whether dystrophic microglia in this young animals also contain
abnormal tau or whether it was exclusive of aged individuals.
In adolescents there were very few dystrophic cells, but those
were also positive for AT100; although AT100-ir was more diffuse
compared to aged animals. Active and resting microglia did not
show AT100-ir (Figure 11).
DISCUSSION
Amyloid Plaques Are Present in Aged
Marmoset, but Abnormal Tau Can Be
Detected from Adolescence
Aβ is a small peptide involved in the pathogenesis of AD in
humans (Zhang et al., 2012), either in the form of compact
or diffuse amyloid plaques (Blennow et al., 2006). Compact
plaques present an amyloid core while diffuse plaques lack a
morphologically identifiable structure and are characterized by
deposits in the parenchyma and around wall vessels (Dickson and
Vickers, 2001). Monkeys have identical Aβ amino acid sequence
to humans (Selkoe et al., 1987), which may result in similar
mechanisms for Aβ production and accumulation. It has widely
been reported that aged non-human primates present amyloid
accumulation in the form of diffuse and compact plaques, mainly
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FIGURE 9 | Representative photomicrographs of microglia
phenotypes: inactive cells (A, from an adolescent subject) with a small
soma size, and long and thin processes. Active cells (B, from an old subject)
with hypertrophy and abundant processes. Dystrophic cells (C,D, from an
aged subject) with clear fragmentation of the cytoplasm and de-ramification
(C), diverse spheroids and shortened tortuous process (D, arrows).
FIGURE 10 | Quantification of resting, active and dystrophic microglia
per area (mm2) in dorsal hippocampus of marmosets at different ages
(A: adolescents, Ad: adults, O: old, and Ag: aged). One way ANOVA, post
hoc analysis Tukey (∗p < 0.05; ∗∗p < 0.01; ∗∗∗p < 0.001).
in the cortex (Cork et al., 1990; Gearing et al., 1996, 1997;
Giannakopoulos et al., 1997; Kimura et al., 2003; Bons et al.,
2006; Lemere et al., 2008; Oikawa et al., 2010; Perez et al., 2013;
Sridharan et al., 2013; Darusman et al., 2014). Amyloid plaques
in the cortex of old marmoset have been previously described as
well (Maclean et al., 2000; Geula et al., 2002). In the present study
we observed Aβ1−40 and Aβ1−42 accumulation in the medial
temporal cortex and adjacent cortical areas of aged marmosets.
We observed Aβ1−42 plaques, mainly in the form of diffuse
plaques, but some large compact plaques were also detected in
the parenchyma. Aβ1−40 diffuse plaques were present mainly
around blood vessels as already described for cerebral amyloid
angiopathy (CAA) in humans (Boulouis et al., 2016); however,
Aβ1−40 compact plaques were not observed. No Aβ staining was
observed in younger animals.
Diffuse plaques can be detected in cognitively intact elderly
people (Mackenzie, 1994; Hof et al., 1996; Mufson et al., 1999;
Rodrigue et al., 2009), and it has been described that they do not
trigger any changes in the neuropil, such as; increase in neurite
curvature, dystrophic neurites, and recruitment of astrocytes
(Masliah et al., 1990; Lombardo et al., 2003). Furthermore,
extracellular diffuse deposits can be detected in the postmortem
brain of Down’s syndrome patients already at 12 years of age
whereas compact plaques are only seen after the third decade,
along with cognitive deficits in Down syndrome subjects (Lemere
et al., 1996). Thus, it has been postulated that diffuse plaques
represent an early stage in AD plaque development whereas
compact plaques are associated with late AD stages and cognitive
decline (Dickson and Vickers, 2001). In our present study,
Aβ1−42 was detected as diffuse and compact plaques in the aged
marmoset. We also observed tau hyperphosphorylation in aged
marmoset. Thus, aged marmoset presents two main hallmarks of
neurodegenerative diseases as AD: compact amyloid plaques and
abnormal tau phosphorylation.
Alzheimer’s disease is considered a multifactorial disease
that progresses over time (Iqbal and Grundke-Iqbal, 2010)
where brain alterations can be detected decades before clinical
symptoms of the disease. Accordingly, it has been postulated
that one pathogenic trigger of neuronal dysfunction comprises
soluble Aβ oligomers, long before formation of amyloid plaques
(Lacor et al., 2004). Soluble Aβ1−42 is considered to be highly
neurotoxic as it can induce mitochondria dysfunction (Cha
et al., 2012), spine loss (Yu and Lu, 2012), membrane fluidity
(Sasahara et al., 2013), and over-excitation of the post-synaptic
neurons (Palop et al., 2007), leading to impaired memory and
cognition (Sengupta et al., 2016). In this study we could not
measure the amount of soluble Aβ as no fresh tissue was
available. Therefore, further studies are needed to determine the
presence of soluble Aβ species in brain and plasma samples,
rather than the fibrillary forms already reported in literature,
to better outline the age of appearance of this peptide in
marmosets.
Abnormally phosphorylated tau protein is a hallmark of
several human neurodegenerative disorders (García-Sierra et al.,
2003; Binder et al., 2005; Ferrer et al., 2014). However,
phosphorylation of tau may also occur under physiological
processes. Physiological based phosphorylation of tau allows
microtubules to disassemble (Lindwall and Cole, 1984), a
phenomenon observed during hibernation (Arendt et al., 2003)
or cellular division (Delobel et al., 2002). Notwithstanding,
in aging (Hof et al., 1996) and neurodegenerative diseases
(i.e., AD, Down syndrome, and tauopathies) an excessive
phosphorylation of tau causes its self-aggregation (Alonso
et al., 2001) in straight and paired-helical filaments which
subsequently form the so called neurofibrillary tangles (NFT).
NFTs cause neuronal dysfunction and eventually lead to death
(Avila et al., 2006; Stokin and Goldstein, 2006). In several
aged non-human primates, hyperphosphorylated tau filaments
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FIGURE 11 | Double labeling of microglia (iba-1) and tau hyperphosphorylation (AT-100) or conformational change (Alz50) in dentate gyrus. Aged
marmoset: Dystrophic microglia presented compact AT100-ir aggregates (blue arrows), but active microglia did not present any AT100-ir (white arrows). In the
polymorphic layer dystrophic microglia show Alz50-ir as large cytoplasmic inclusions (blue arrows), whereas in the molecular layer, active microglia (white arrows) do
not present any Alz50-ir. A magnification of the polymorphic layer showed dystrophic microglia with fragmented processes and Alz50-ir (∗), while neighboring cells
were not positive for iba-1. Adolescent marmoset: Dystrophic microglia present AT100-ir as diffuse inclusions.
have been observed in hippocampus and cortex of old subjects
(Härtig et al., 2000; Schultz et al., 2000a,b; Oikawa et al., 2010;
Perez et al., 2013; Darusman et al., 2014). To our knowledge,
there are no previous reports of hyperphosphorylated tau in
marmosets. In this study, adolescent animals (1.6–5 years of age)
already showed hyperphosphorylated tau (AT-100 and pTau231),
while old subjects (>8 years-old) had a dramatically increased
immunolabeling in parietal, temporal, and entorhinal cortices,
and in the hippocampus. Also, conformational changes in tau
(Alz50-ir) were detected from adolescence, and increased with
age. Our results coincide with the study of Perez et al. (2013)
in Gorilla gorilla, where Alz50-ir fibers were observed at each
age analyzed (13–55 years of age). In Papio anubis (Schultz
et al., 2000b), Papio hamadryas (Schultz et al., 2000a), Macaca
fascicularis (Oikawa et al., 2010; Darusman et al., 2014), and
Macaca mulatta (Härtig et al., 2000) hyperphosphorylated tau
appears until the second decade of life. This could suggest that the
beginning of tau hyperphosphorylation process varies between
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different species of non-human primates, the marmosets being
heavily prone to be affected.
In order to better understand the association between the
hyperphosphorylation of tau and its conformational changes, we
performed a correlation analysis between pTau231/AT100 and
Alz-50 for each marmoset (all ages). We observed that both
markers increase proportionally to each other in most of the brain
regions; however, pTau231 showed a better correlation index in
the entorhinal and parietal cortices (Figure 8). In AD, the spread
of tau pathology from entorhinal cortex to the limbic region
(hippocampus) takes several years to progress (Braak and Braak,
1991). Therefore, in agreement with human studies, abnormal tau
phosphorylation was higher in entorhinal cortex than in other
brain areas, and progresses over the years to hippocampal region
in the marmoset brain (Figure 3).
Conformational changes of tau were detected by Alz50
antibody. When, tau markers were correlated with age, Alz50
presented the lowest correlation index as it increased only in
the aged marmosets whereas pTau231 and AT100 increased
constantly since adolescence (Supplementary Figure S1).
A recent analysis of 2,332 brains of 1- to 100-year-old individuals,
clearly showed that, in humans, hyperphosphorylation of
tau commences before puberty or in early adulthood and
accumulates along aging until NFTs can be observed (Braak
et al., 2011). Moreover, previous studies have described that
hyperphosphorylation of tau must precede the appearance of
tau aggregates and/or its conformational changes (as detected
by Alz-50; Alonso et al., 2001; García-Sierra et al., 2003). This
previous reports are in accordance to our present observation
where tau hyperphosphorylation was more abundant than tau
conformational changes in the marmoset. Interestingly, the
distribution patterns of amyloid plaques were different from the
one of tau pathology (amyloid plaques were found only in cortex,
while abnormal tau was present in cortex and hippocampus),
suggesting that these lesions develop independently from
each other. Then, in the marmoset, Aβ deposition is not a
necessary precondition for hyperphosphorylation of tau, as
already suggested by other authors (Iqbal and Grundke-Iqbal,
2010; Iqbal et al., 2014).
Dystrophic Microglia in Marmoset
In murine models of AD, amyloid plaques formation is followed
by the appearance of activated microglia. Streit et al. (2004)
argued that in aged humans, microglia normally senesce and
undergo microglial dystrophy that, in some cases, involves a
process of cytorrhexis. While this latter process can be observed
in normal aging brains, it is more frequently observed in
neurodegenerative diseases, such as AD (Streit et al., 2004, 2009).
In this study, we classified the morphology of microglia as
inactive, active, and dystrophic; and quantified them according
to the age. There was a decreased number of resting microglia
along aging. Active cells showed a more homogeneous presence
in all ages, while dystrophic microglia increased in aged animals
compared to adolescent and adults. These results coincide with
data from patients suffering neurodegenerative diseases where
there is a pronounced increase of dystrophic microglia (AD,
Huntington’s Disease, Creutzfeldt-Jakob disease; von Eitzen et al.,
1998; Wierzba-Bobrowicz et al., 2004; Simmons et al., 2007;
Streit et al., 2009; Xue and Streit, 2011), highlighting the role
of microglia in neurodegenerative diseases. It is important to
mention that, in contrast to AD where active microglia proliferate
around amyloid plaques, dystrophic microglia in the marmoset
was found in brain of adolescent and adult marmoset without
apparent amyloid deposition.
Abnormal Tau Is Present Only in the
Dystrophic Microglia
Notably, in the present study dystrophic microglia was Alz50-ir
(widely spread in cytoplasm), and AT100-ir positive (in the form
of inclusions). This pattern of immunoreactivity was observed in
both the few dystrophic cells found in adolescent individuals and
the large amount of dystrophic cells found in the aged animals.
In contrast, active microglia were always negative for Alz50 and
AT100 in all ages tested.
The mechanisms leading to elevated tau
hyperphosphorylation and its aggregation in neurodegenerative
diseases still remain unclear. On the one side, neuroinflammation
has been implicated in driving hyperphosphorylation and
aggregation of tau and neurodegeneration in humans (Gebicke-
Haerter, 2001; Ishizawa and Dickson, 2001; Bellucci et al.,
2011) and various models of tauopathies (Bellucci et al., 2004;
Zilka et al., 2009). In the 3xTg mouse model of AD, induction
of systemic inflammation with lipopolysaccharide resulted in
enhanced microglial activation and tau pathology (Kitazawa,
2005). The microglial fractalkine receptor (CX3CR1) knockout
mice (hTauCx3cr1-/-) showed enhanced microglia-specific
neuroinflammation, accompanied by an accelerated onset
and progression of tau pathology, cognitive dysfunction and
neurodegeneration (Maphis et al., 2015). Furthermore, microglial
activation preceded tau pathology and synaptic loss in the P301S
mouse model of tauopathy, while administration of FK506,
an anti-inflammatory compound, reduced tau pathology and
prolonged the lifespan of these mice (Yoshiyama et al., 2007).
On the other hand, more recent research proposes a
neuroprotective role of microglia. Increased intracellular levels of
phosphorylated tau could be detrimental to neurons. Thus, tau
secretion might be a mechanism by which excess of neuronal tau
is removed to prevent toxicity. The spread of tau from cell to
cell has been proposed to be one of the mechanisms underlying
the progression of tau pathologies (Holmes et al., 2013, 2014).
Recent studies demonstrate that microglia are involved in the
uptake of tau protein. In primary cultures of microglia (Luo
et al., 2015; Bolós et al., 2016) and P301S mice (Luo et al.,
2015), microglia internalize extracellular soluble and insoluble
tau in vitro and in vivo, respectively. Thus, microglia seem to
play a protective mechanism in the clearance of tau. Furthermore,
a deficiency in the capacity of microglia to internalize and
degrade extracellular toxic proteins might be related to a
higher incidence of neurodegenerative disease. Among the newly
identified AD-risk genes, many are important regulators of innate
immunity, including the antigen-presenting and phagocytic and
degradative functions of circulating macrophages and microglia
(Griciuc et al., 2013; Guerreiro et al., 2013; Borroni et al., 2014;
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Kleinberger et al., 2014). An arginine-to-histidine substitution
at amino acid 47 (R47H) in the triggering receptor expressed
on myeloid cells 2 (TREM2) gene, which regulates microglial
function in the CNS, increased the risk of developing late-onset
AD (Guerreiro et al., 2013).
Promoting the uptake of tau aggregates into microglia could
be of great importance in the development of more effective
therapies against AD and other tauopathies. In mouse models
of tau-dependent neurodegeneration, passive immunization with
anti-tau monoclonal antibodies has been shown to reduce age-
dependent tau pathology, including NFTs, neurodegeneration
and behavioral impairment (Asuni et al., 2007; Bi et al.,
2011; Boutajangout et al., 2011; Chai et al., 2011; Yanamandra
et al., 2013). Furthermore, two different antibodies (HJ8.5 and
HJ9.4) were able to increase tau clearance via microglia and a
parallel block of tau uptake into neurons, in a size-dependent
manner (Funk et al., 2015). Still, whether microglia will undergo
neurodegeneration after tau uptake or whether these cells will
actively function in later stages remains unclear.
In the present study, the high amounts of hyperphosphorylated
tau observed in the dystrophic microglia of aged marmoset
could suggest that long termed tau-phagocytosis triggers the
dystrophic process since hyperphosphorylated tau appears early
in the adolescence.
In summary, marmosets seem to be a valuable prospect species
for aging research as they present important hallmarks of human
brain aging and neurodegeneration.
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